Moringa Acquisition Corp
MACA
NASDAQ Capital Market9.46
USD
-1.50
- -
CIK
0001835416
ISIN
KYG6S23K1085
CUSIP
G6S23K108
Return %
Stock
S&P500
1Y
-12.89
26.84
3Y
-2.27
77.03
5Y
-5.40
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ilan Levin
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 250 Park Avenue New York City NY United States of America 10177
- IPO Date
- Apr 7, 2021
- CIK
- 0001835416
- Website
- moringaac.com
- Similar Companies
- Business
- Moringa Acquisition Corp is a special purpose acquisition company (SPAC) based in New York, established in 2020, primarily focused on acquiring or merging with innovative technology and biotechnology companies. It engages in strategic business combinations including mergers, share exchanges, asset acquisitions, and recapitalizations. The company’s notable recent business combination involved a reverse merger with Silexion Therapeutics Ltd., a clinical-stage, oncology-focused biotechnology company specializing in the development of siRNA-based therapies targeting solid tumor cancers with mutated KRAS oncogenes. Through this combination completed in August 2024, Moringa Acquisition Corp transitioned from a SPAC entity to a publicly listed biotechnology firm under Silexion Therapeutics. Its main offerings now include advancing therapeutic innovations for solid tumor cancers, conducting clinical trials, and developing oncology drug candidates, with a focus on locally advanced pancreatic cancer treatment. This transaction granted the combined company enhanced financial and strategic flexibility to pursue siRNA therapeutic development. Moringa Acquisition Corp originally focused on technology-based acquisitions primarily in Israel but has shifted its operations towards clinical biotechnology and oncology therapeutics through its merger with Silexion. The company trades on Nasdaq under the ticker MACA until the merger, with its successor listed under new tickers. This strategic shift exemplifies its expansion from a financial acquisition vehicle to an operational biotech firm targeting unmet needs in cancer therapies.
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION